Skip to main content
Lotus Pharm logo

Lotus Pharm — Investor Relations & Filings

Ticker · 1795 ISIN · TW0001795003 LEI · 984500BEECDBC04KP716 TW Manufacturing
Open in API
Filings indexed 2,734 across all filing types
Latest filing 2021-11-18 Regulatory Filings
Country TW Taiwan
Listing TW 1795

About Lotus Pharm

http://www.lotuspharm.com.tw

Lotus Pharmaceutical Co., Ltd. is a global specialty organization focused on the development, manufacturing, and commercialization of high-barrier generic and specialty medicines. The company specializes in complex generics, with a primary focus on oncology, immunology, and addiction treatment. Its portfolio includes technically demanding products such as Lenalidomide, Suboxone, Nintedanib, and Vinorelbine, as well as an advancing pipeline of biosimilars and 505(b)(2) oncology candidates. Utilizing an integrated R&D and manufacturing platform, the company executes a "2x2" growth strategy centered on dual market expansion and product diversification. Its commercial footprint spans over 90 markets globally, maintaining a strong presence in the Asia-Pacific region and the United States. The company prioritizes high technical entry barriers and cost-effective therapeutic solutions to improve global patient access to essential medications.

Recent filings

Filing Released Lang Actions
澄清財訊快報110/11/18報導
Regulatory Filings Classification · 95% confidence The document is a short announcement clarifying a media report about the company's financial performance. It explicitly states that the company has not prepared financial forecasts and that actual financial results are available on the public information observatory. The document is only 734 characters long and serves to clarify information rather than present any financial data or detailed report. It does not contain financial statements, management discussion, or any detailed report content. Therefore, it is an announcement clarifying information, fitting best under Regulatory Filings (RNS) as a general regulatory announcement or clarification.
2021-11-18 Chinese
110年11月法人說明會簡報 — 179520211123E001.pdf
Investor Presentation Classification · 95% confidence The document is titled 'THIRD QUARTER 2021 RESULTS Investor Presentation' and contains detailed financial data for Q3 2021, including revenue, gross margin, operating expenses, net income, and EPS. It also includes business highlights, market leadership information, regulatory updates, R&D pipeline status, and capital structure details. The content is comprehensive and focused on quarterly financial performance and strategic updates, typical of an investor presentation. The length is substantial (15,000 characters), indicating it is the full presentation rather than a brief announcement. Therefore, the document fits the category of an Investor Presentation (IP).
2021-11-16 Chinese
110年11月法人說明會簡報 — 179520211123M001.pdf
Interim / Quarterly Report Classification · 95% confidence The document is a detailed presentation of Q3 2021 operational and financial results for a company, including financial performance, product market share, R&D progress, and strategic initiatives. It contains substantive financial data such as revenue, gross profit, EPS, and operating income for the quarter and year-to-date periods. The document also includes forward-looking statements and detailed business updates typical of quarterly earnings presentations. It is not a full annual report (10-K), but a comprehensive quarterly report with financial statements and analysis. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2021
2021-11-16 Chinese
110年11月法人說明會簡報 — 179520211116E001.pdf
Investor Presentation Classification · 95% confidence The document is titled 'THIRD QUARTER 2021 RESULTS Investor Presentation' and contains detailed financial data for Q3 2021, including revenue, gross margin, net income, EPS, and operational highlights. It also includes business highlights, market leadership, regulatory updates, R&D pipeline, and capital structure information. The presence of forward-looking statements, detailed financial review, and strategic deliverables aimed at investors strongly indicates this is an investor presentation. The document length is substantial (15,000 characters), and it contains substantive financial data and analysis, not just an announcement or summary. Therefore, it fits the category of an Investor Presentation (IP).
2021-11-16 Chinese
110年11月法人說明會簡報 — 179520211116M001.pdf
Interim / Quarterly Report Classification · 95% confidence The document is a detailed presentation of the company's Q3 2021 operational and financial results, including financial performance, product market share, R&D progress, and strategic initiatives. It contains substantive financial data such as revenue, gross profit, operating income, EPS, and market analysis. The presence of quarterly financial figures and operational updates indicates this is a comprehensive interim or quarterly report rather than a brief earnings release or an investor presentation. The document length (over 12,000 characters) and detailed financial tables support this classification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q3 2021
2021-11-16 Chinese
110年11月法人說明會簡報
Investor Presentation Classification · 95% confidence The document is a listing of scheduled investor presentations or analyst meetings (法人說明會) with dates, times, and links to presentation materials. It includes references to financial and operational status explanations to investors, typical of investor presentations. The document is short (1245 characters) and does not contain actual financial statements or detailed financial analysis. It is not an announcement of a report publication but a schedule and summary of investor presentations. Therefore, the document best fits the category of Investor Presentation (IP).
2021-11-16 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.